Chongqing Lummy Pharmaceutical (300006) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Chongqing Lummy Pharmaceutical ¥1.13, price ¥5.56, upside -79.7%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Chongqing Lummy Pharmaceutical for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range ¥2.20 – ¥11.34 · fair‑value band ¥1.04 – ¥1.23 · the ¥5.56 price screens above the ¥1.13 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Chongqing Lummy Pharmaceutical in your weekly email
Every Wednesday you see whether Chongqing Lummy Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China.
Show more
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. The company was founded in 1999 and is headquartered in Chongqing, China.
Stock analysis
Chongqing Lummy Pharmaceutical (300006) currently trades at ¥5.56, while our model-based Fair Value estimate is ¥1.13, implying the stock looks roughly 392.1% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥1.11 per share, and 0 of the 9 models we run sit above the ¥5.56 price.
Bear case: the Multiples group reads lowest at ¥1.07, and 9 of the 9 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥1.04 (bear) to ¥1.23 (bull), the price of ¥5.56 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Chongqing Lummy Pharmaceutical reported revenue of 769M CNY in FY2025 versus 1.2B CNY in FY2021, a compound −11.0%/yr. Reported net income was −135M CNY in FY2025.
Key figures
Market cap 5.9B CNY (≈ $877M) · P/S ratio 7.09 · EPS (TTM) ¥−0.1300 · Dividend yield 0.2% · Net margin −17.5% · Return on equity −7.0% · Return on assets (EBIT) −2.2% · Operating margin −3.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 31% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −80%, 300006 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.1100 to ¥1.13). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥1.04Fair Value ¥1.13Bull ¥1.23
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−3.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.5%
Start year 2020 (pandemic). Over 10 years: −2.2% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−21.9% (2020) → −13.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+61.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +58.7% a year for the price.
Compare Chongqing Lummy Pharmaceutical with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside−80% · Bottom 25%
Profitability
Return on assets−2% · Bottom 25%
Net margin (TTM)−18% · Bottom 25%
Operating margin (TTM)−3% · Bottom 25%
Growth and dividend
Revenue growth−8% · Bottom 25%
Dividend yield (TTM)0.2% · Bottom 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/B0.50× · Cheapest 25%
P/S (TTM)1.15× · Cheapest 25%
P/FCF37.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 18
FUTURE (revenue growth)0· sector 29
PAST (return on equity)0· sector 52
HEALTH (low debt)98· sector 94
DIVIDEND (yield)5· sector 42
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Chongqing Lummy Pharmaceutical (300006) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥1.13 versus a price of ¥5.56, about −80% upside (overvalued).
What is the fair value of 300006?
Our model-based fair value for Chongqing Lummy Pharmaceutical is ¥1.13 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥5.56.
What is the quality score of 300006?
Chongqing Lummy Pharmaceutical has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Chongqing Lummy Pharmaceutical (300006)?
Our model-based price target is the fair value of ¥1.13 (as of Sep 23, 2026) from 9 valuation models. Cautious scenario ¥1.04, optimistic scenario ¥1.23. It is a calculation from audited fundamentals, not an analyst target.
What is the Chongqing Lummy Pharmaceutical stock forecast for 2026?
Our models put fair value at ¥1.13, about −80% upside versus a price of ¥5.56 (overvalued). Cautious scenario ¥1.04, optimistic scenario ¥1.23. The calculation is refreshed regularly with new filings.
What is the revenue of Chongqing Lummy Pharmaceutical (300006)?
Chongqing Lummy Pharmaceutical reported trailing-twelve-month revenue of about 760M CNY (latest available figure, as of Sep 23, 2026).
Does Chongqing Lummy Pharmaceutical pay a dividend?
Chongqing Lummy Pharmaceutical currently shows a dividend yield of about 0.23% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Chongqing Lummy Pharmaceutical (300006)?
For today's price to be fair in a discounted-cash-flow model, Chongqing Lummy Pharmaceutical would have to grow free cash flow by +61.3 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -13.5 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of 300006 use?
Our models discount Chongqing Lummy Pharmaceutical at 10.4 %: a base by market capitalisation (small), damped by beta 0.33, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Chongqing Lummy Pharmaceutical that is +61.3 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Chongqing Lummy Pharmaceutical (300006) delivered so far?
Over the past 5 years revenue at Chongqing Lummy Pharmaceutical grew -13.5 % a year. The price currently implies +61.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Chongqing Lummy Pharmaceutical (300006) growing?
The median revenue growth in the sector is +4.1 % a year. That is the yardstick for the growth priced into Chongqing Lummy Pharmaceutical (+61.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Chongqing Lummy Pharmaceutical (300006)?
The free-cash-flow yield on the price is 0.39 %: that much free cash flow Chongqing Lummy Pharmaceutical produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Chongqing Lummy Pharmaceutical (300006)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Chongqing Lummy Pharmaceutical it is ¥1.13 per share (as of Sep 23, 2026), against a price of ¥5.56. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Chongqing Lummy Pharmaceutical stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 300006 trades above its calculated fair value: price ¥5.56, fair value ¥1.13, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300006?
No. The price is what the market pays today (¥5.56); the fair value is what the company's own numbers justify (¥1.13). For Chongqing Lummy Pharmaceutical the two are ¥4.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is Chongqing Lummy Pharmaceutical worth?
The market values Chongqing Lummy Pharmaceutical at about 5.9B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥5.56; our models calculate a fair value of ¥1.13 per share.
What do the bullish and bearish scenarios say about 300006?
Our models span a range for Chongqing Lummy Pharmaceutical: cautious scenario ¥1.04, base ¥1.13, optimistic ¥1.23 per share (as of Sep 23, 2026, price ¥5.56). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Chongqing Lummy Pharmaceutical (300006)?
Balance-sheet figures for Chongqing Lummy Pharmaceutical (as of Sep 23, 2026): return on equity −7.0%, debt of 0.03 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 300006 from its 52-week high?
Chongqing Lummy Pharmaceutical trades at ¥5.56, about 16% below its 52-week high of ¥6.58 and 31% above the low of ¥4.25 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.13 is for.
Which stocks are comparable to Chongqing Lummy Pharmaceutical?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Chongqing Lummy Pharmaceutical stock attractive at the current price?
The data as of Sep 23, 2026: price ¥5.56, calculated fair value ¥1.13 (−80%), Quality Score 50/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300006 calculated?
We run Chongqing Lummy Pharmaceutical through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥1.13, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Chongqing Lummy Pharmaceutical itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Chongqing Lummy Pharmaceutical (300006)?
The closing price on Sep 22, 2026 was ¥5.56. Our model-based fair value is ¥1.13, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Chongqing Lummy Pharmaceutical right now?
The price sits above even our optimistic bull case (¥1.23). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Chongqing Lummy Pharmaceutical
How large is the market capitalisation of Chongqing Lummy Pharmaceutical (300006)?
The market capitalisation of Chongqing Lummy Pharmaceutical is 5.9B CNY (≈ $877M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Chongqing Lummy Pharmaceutical (300006)?
The price-to-sales ratio of Chongqing Lummy Pharmaceutical is 7.09 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Chongqing Lummy Pharmaceutical (300006)?
Earnings per share at Chongqing Lummy Pharmaceutical are ¥−0.1300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Chongqing Lummy Pharmaceutical (300006)?
The dividend yield of Chongqing Lummy Pharmaceutical is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Chongqing Lummy Pharmaceutical (300006)?
The net margin of Chongqing Lummy Pharmaceutical is −17.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Chongqing Lummy Pharmaceutical (300006)?
The return on equity (ROE) of Chongqing Lummy Pharmaceutical is −7.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Chongqing Lummy Pharmaceutical (300006)?
On an EBIT basis the return on assets of Chongqing Lummy Pharmaceutical is −2.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Chongqing Lummy Pharmaceutical (300006)?
The operating margin of Chongqing Lummy Pharmaceutical is −3.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Chongqing Lummy Pharmaceutical (300006)?
Revenue at Chongqing Lummy Pharmaceutical is growing −8.2% versus a year earlier (3y avg −4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Chongqing Lummy Pharmaceutical (300006)?
Earnings per share at Chongqing Lummy Pharmaceutical are growing −61.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Chongqing Lummy Pharmaceutical (300006) hold?
Chongqing Lummy Pharmaceutical holds more cash than debt, 503M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Chongqing Lummy Pharmaceutical in the live analysis
One click puts Chongqing Lummy Pharmaceutical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
